PacBio CFO Departs; New Directors Appointed

Ticker: PACB · Form: 8-K · Filed: 2025-03-27T00:00:00.000Z

Sentiment: neutral

Topics: management-change, board-composition, cfo-departure

Related Tickers: PACB

TL;DR

PacBio CFO out, interim CFO in, two new board members added.

AI Summary

Pacific Biosciences of California, Inc. (PacBio) announced on March 24, 2025, the departure of its Chief Financial Officer, Christian O. Knutson, effective March 21, 2025. The company also announced the appointment of Sarah E. Johnson as interim CFO, effective March 21, 2025. Additionally, the company elected two new directors, Dr. Jonathan M. Rothberg and Dr. Richard K. King, to its Board of Directors.

Why It Matters

Changes in key financial and board leadership can signal strategic shifts or internal challenges, impacting investor confidence and the company's future direction.

Risk Assessment

Risk Level: medium — Changes in CFO and board composition can introduce uncertainty regarding financial strategy and corporate governance.

Key Players & Entities

FAQ

Who has been appointed as the interim Chief Financial Officer of Pacific Biosciences?

Sarah E. Johnson has been appointed as the interim Chief Financial Officer, effective March 21, 2025.

When did Christian O. Knutson's departure as CFO become effective?

Christian O. Knutson's departure as Chief Financial Officer was effective March 21, 2025.

Who are the new directors elected to the Board of Directors?

Dr. Jonathan M. Rothberg and Dr. Richard K. King have been elected as new directors.

What is the exact date of this Form 8-K filing?

The Form 8-K was filed on March 27, 2025, reporting events as of March 24, 2025.

What is the principal executive office address for Pacific Biosciences?

The principal executive offices are located at 1305 O'Brien Drive, Menlo Park, California 94025.

From the Filing

0001299130-25-000072.txt : 20250327 0001299130-25-000072.hdr.sgml : 20250327 20250327090747 ACCESSION NUMBER: 0001299130-25-000072 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20250324 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20250327 DATE AS OF CHANGE: 20250327 FILER: COMPANY DATA: COMPANY CONFORMED NAME: PACIFIC BIOSCIENCES OF CALIFORNIA, INC. CENTRAL INDEX KEY: 0001299130 STANDARD INDUSTRIAL CLASSIFICATION: LABORATORY ANALYTICAL INSTRUMENTS [3826] ORGANIZATION NAME: 08 Industrial Applications and Services EIN: 161590339 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-34899 FILM NUMBER: 25775649 BUSINESS ADDRESS: STREET 1: 1305 O'BRIEN DRIVE CITY: MENLO PARK STATE: CA ZIP: 94025 BUSINESS PHONE: 650-521-8000 MAIL ADDRESS: STREET 1: 1305 O'BRIEN DRIVE CITY: MENLO PARK STATE: CA ZIP: 94025 FORMER COMPANY: FORMER CONFORMED NAME: PACIFIC BIOSCIENCES OF CALIFORNIA INC DATE OF NAME CHANGE: 20050829 FORMER COMPANY: FORMER CONFORMED NAME: NANOFLUIDICS INC DATE OF NAME CHANGE: 20040729 8-K 1 pacb-20250324.htm 8-K pacb-20250324 0001299130 false 0001299130 2025-03-24 2025-03-24 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 24, 2025 Pacific Biosciences of California, Inc. (Exact name of registrant as specified in its charter) Delaware 001-34899 16-1590339 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.) 1305 O’Brien Drive Menlo Park , California 94025 (Address of principal executive offices) (Zip Code) ( 650 ) 521-8000 (Registrant’s telephone number, including area code) (Former name or former address, if changed since last report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $0.001 per share PACB The NASDAQ Stock Market LLC Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company o If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o ITEM 5.02.    DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF CERTAIN OFFICERS; COMPENSATORY ARRANGEMENTS OF CERTAIN OFFICERS. On March 24, 2025, Pacific Biosciences of California, Inc. (the “Company”) entered into an offer letter with Jim R. Gibson to serve as its Chief Financial Officer. Mr. Gibson will be appointed as the Company’s Chief Financial Officer and principal financial officer effective as of as his first date of employment, which is ant

View on Read The Filing